Terumo Blood and Cell Technologies collaborates with Eliaz Therapeutics in the development and commercialization of a novel therapeutic apheresis treatment for acute kidney injury (AKI) July 27, 2022 GlobeNewswire Source: Medical Share on Facebook Share Share on TwitterTweet Share on Google Plus Share Share on Pinterest Share Share on LinkedIn Share Share on Digg Share